GlassScriptPhysician profile
Anju Agarwal
NPI 1164734620
$2,101.42
in general payments reported to CMS, 2019-2025
32 companies · $307 in 2025
The $307 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.25 · 2021: $13.34 · 2022: $408 · 2023: $174 · 2024: $1,183 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,664.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $343.08 | 2022-2025 | Evenity, Tepezza |
| Medtronic, INC. | $225.42 | 2022-2025 | Minimed 780g |
| Lilly USA, LLC | $202.53 | 2022-2024 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $160.89 | 2022-2024 | |
| Dexcom, INC. | $146.66 | 2022-2025 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $141.46 | 2024 | Ilet Bionic Pancreas |
| Novo Nordisk INC | $85.72 | 2022-2024 | Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $84.37 | 2022-2024 | Recorlev, Gvoke Hypopen |
| Abbvie INC. | $73.64 | 2022-2024 | Synthroid |
| Novartis Pharmaceuticals Corporation | $45.73 | 2024 | |
| Abbott Laboratories | $45.35 | 2022-2023 | Freestyle Libre 3 |
| Almatica Pharma LLC | $41.61 | 2024 | Teriparatide, Loreev Xr |
| Madrigal Pharmaceuticals | $41.53 | 2024-2025 | Resmetirom, Rezdiffra |
| Alexion Pharmaceuticals, INC. | $39.27 | 2024-2025 | Strensiq |
| Insulet Corporation | $38.57 | 2022-2024 | Omnipod |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $37.76 | 2022-2025 | |
| Radius Health, INC. | $36.49 | 2022-2024 | Tymlos |
| Amneal Pharmaceuticals LLC | $33.28 | 2022-2025 | Unithroid |
| Astrazeneca Pharmaceuticals LP | $30.43 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $28.35 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $25.05 | 2022 | |
| Ibsa Pharma INC. | $23.89 | 2025 | Licart, Flector, Tirosint |
| Astellas Pharma US INC | $23.73 | 2025 | Cresemba |
| Rhythm Pharmaceuticals, INC. | $19.78 | 2024 | Imcivree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.44 | 2024 | Jardiance |
| Nevro Corp. | $18.39 | 2024 | Senza |
| Corcept Therapeutics | $16.50 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.25 | 2020 | |
| Pfizer INC. | $15.03 | 2024 | |
| Kyowa Kirin, INC. | $14.83 | 2024 | Crysvita |
| Tolmar, INC. | $14.22 | 2024 | |
| Chiesi USA, INC. | $13.17 | 2024 | Myalept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anju Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.